<?xml version='1.0' encoding='utf-8'?>
<document id="26347996"><sentence text="Influence of verapamil on pharmacokinetics of pristimerin in rats."><entity charOffset="13-22" id="DDI-PubMed.26347996.s1.e0" text="verapamil" /><entity charOffset="46-57" id="DDI-PubMed.26347996.s1.e1" text="pristimerin" /><pair ddi="false" e1="DDI-PubMed.26347996.s1.e0" e2="DDI-PubMed.26347996.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26347996.s1.e0" e2="DDI-PubMed.26347996.s1.e1" /></sentence><sentence text="The aim of this study was to investigate the effects of verapamil on the pharmacokinetics of pristimerin in rats"><entity charOffset="56-65" id="DDI-PubMed.26347996.s2.e0" text="verapamil" /><entity charOffset="93-104" id="DDI-PubMed.26347996.s2.e1" text="pristimerin" /><pair ddi="false" e1="DDI-PubMed.26347996.s2.e0" e2="DDI-PubMed.26347996.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26347996.s2.e0" e2="DDI-PubMed.26347996.s2.e1" /></sentence><sentence text=" A sensitive and reliable LC-MS/MS method was developed and applied for the determination of pristimerin in rat plasma"><entity charOffset="93-104" id="DDI-PubMed.26347996.s3.e0" text="pristimerin" /></sentence><sentence text=" The pharmacokinetics of orally administered pristimerin with and without verapamil pretreatment was investigated"><entity charOffset="45-56" id="DDI-PubMed.26347996.s4.e0" text="pristimerin" /><entity charOffset="74-83" id="DDI-PubMed.26347996.s4.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.26347996.s4.e0" e2="DDI-PubMed.26347996.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26347996.s4.e0" e2="DDI-PubMed.26347996.s4.e1" /></sentence><sentence text=" The results indicated that, when the rats were pretreated with verapamil, the peak concentration of pristimerin increased from 189"><entity charOffset="64-73" id="DDI-PubMed.26347996.s5.e0" text="verapamil" /><entity charOffset="101-112" id="DDI-PubMed.26347996.s5.e1" text="pristimerin" /><pair ddi="false" e1="DDI-PubMed.26347996.s5.e0" e2="DDI-PubMed.26347996.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26347996.s5.e0" e2="DDI-PubMed.26347996.s5.e1" /></sentence><sentence text="13 to 277" /><sentence text="53 ng/mL (46" /><sentence text="7%), and the AUC0-t increased by approximately 82" /><sentence text="0%" /><sentence text=" Additionally, the effects of verapamil on the absorption and metabolic stability of pristimerin were investigated using the Caco-2 cell transwell model and rat liver microsomes"><entity charOffset="30-39" id="DDI-PubMed.26347996.s10.e0" text="verapamil" /><entity charOffset="85-96" id="DDI-PubMed.26347996.s10.e1" text="pristimerin" /><pair ddi="false" e1="DDI-PubMed.26347996.s10.e0" e2="DDI-PubMed.26347996.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26347996.s10.e0" e2="DDI-PubMed.26347996.s10.e1" /></sentence><sentence text=" A markedly higher transport of pristimerin across the Caco-2 cells was observed in the basolateral-to-apical direction and was abrogated in the presence of the P-gp inhibitor, verapamil" /><sentence text=" These results indicated that P-gp might be involved in the absorption of pristimerin"><entity charOffset="74-85" id="DDI-PubMed.26347996.s12.e0" text="pristimerin" /></sentence><sentence text=" Of note, the metabolic half-life of pristimerin was prolonged by the pretreatment with verapamil"><entity charOffset="37-48" id="DDI-PubMed.26347996.s13.e0" text="pristimerin" /><entity charOffset="88-97" id="DDI-PubMed.26347996.s13.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.26347996.s13.e0" e2="DDI-PubMed.26347996.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26347996.s13.e0" e2="DDI-PubMed.26347996.s13.e1" /></sentence><sentence text=" In conclusion, verapamil could affect the pharmacokinetics of pristimerin, and it might work through increasing the absorption of pristimerin by inhibiting P-gp, or through slowing down the metabolism of pristimerin in the rat liver"><entity charOffset="16-25" id="DDI-PubMed.26347996.s14.e0" text="verapamil" /><entity charOffset="63-74" id="DDI-PubMed.26347996.s14.e1" text="pristimerin" /><entity charOffset="131-142" id="DDI-PubMed.26347996.s14.e2" text="pristimerin" /><entity charOffset="205-216" id="DDI-PubMed.26347996.s14.e3" text="pristimerin" /><pair ddi="false" e1="DDI-PubMed.26347996.s14.e0" e2="DDI-PubMed.26347996.s14.e0" /><pair ddi="false" e1="DDI-PubMed.26347996.s14.e0" e2="DDI-PubMed.26347996.s14.e1" /><pair ddi="false" e1="DDI-PubMed.26347996.s14.e0" e2="DDI-PubMed.26347996.s14.e2" /><pair ddi="false" e1="DDI-PubMed.26347996.s14.e0" e2="DDI-PubMed.26347996.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26347996.s14.e1" e2="DDI-PubMed.26347996.s14.e1" /><pair ddi="false" e1="DDI-PubMed.26347996.s14.e1" e2="DDI-PubMed.26347996.s14.e2" /><pair ddi="false" e1="DDI-PubMed.26347996.s14.e1" e2="DDI-PubMed.26347996.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26347996.s14.e2" e2="DDI-PubMed.26347996.s14.e2" /><pair ddi="false" e1="DDI-PubMed.26347996.s14.e2" e2="DDI-PubMed.26347996.s14.e3" /></sentence><sentence text=" Copyright © 2015 John Wiley &amp; Sons, Ltd" /><sentence text=" " /></document>